ESTRO 2024 - Abstract Book

S4399

Physics - Intra-fraction motion management and real-time adaptive radiotherapy

ESTRO 2024

[1] Borman, P., Uijtewaal, P., Akdag, O., Woodhead, P., Raaymakers, B., & Fast, M. (2022). Technical feasibility of real time cardiorespiratory motion mitigation using MRI-guided MLC-tracking on the Unity MR-linac. Medical Physics, 49(6), E319. [2] Uijtewaal, P, Borman, P, Woodhead, P, Hackett, S, Raaymakers, B, Fast, M. (2021). Dosimetric evaluation of MRI ‐ guided multi ‐ leaf collimator tracking and trailing for lung stereotactic body radiation therapy. Med Phys., 48(4), 1520– 32. [3] Uijtewaal, P., Côte, B., Foppen, T., de Vries, J., Woodings, S., Borman, P., Lambert-Girard, S., Therriault-Proulx, F., Raaymakers, B., Fast, M. (2023). Performance of the HYPERSCINT scintillation dosimetry research platform for the 1.5 T MR-linac. PMB, 68, 04NT01.

3141

Mini-Oral

Evaluation of On-table Adaptive Plan Quality from the Multi-Center Phase 2 SMART Pancreas Trial

Joshua P Kim 1 , Michael D Chuong 2 , Parag J Parikh 1 , Percy Lee 3 , Daniel A Low 4 , Michael F Bassetti 5 , Carri K Glide-Hurst 5 , Ann C Raldow 4 , Yingli Yang 6 , Lorraine Portelance 7 , Kyle R Padgett 7 , Bassem Zaki 8 , Rongxiao Zhang 8 , Hyun Kim 9 , Lauren E Henke 10 , Alex T Price 10 , Joseph D Mancias 11 , Christopher L Williams 12 , John Ng 13 , Ryan Pennell 14 , M. Raphael Pfeffer 15 , Daphne Levin 15 , Karen E Mooney 16 , Amish P Shah 17 , Kathryn E Mittauer 2 1 Henry Ford Health, Radiation Oncology, Detroit, USA. 2 Miami Cancer Institute, Radiation Oncology, Miami, USA. 3 City of Hope, Radiation Oncology, Irvine, USA. 4 UCLA, Radiation Oncology, Los Angeles, USA. 5 University of Wisconsin, Human Oncology, Madison, USA. 6 Ruijin Hospital, Radiology, Shanghai, China. 7 University of Miami, Radiation Oncology, Miami, USA. 8 Dartmouth Hitchcock Medical Center, Radiation Oncology, Lebanon, USA. 9 Washington University School of Medicine, Radiation Oncology, St Louis, USA. 10 University Hospitals, Radiation Oncology, Cleveland, USA. 11 Dana-Farber Cancer Institute, Radiation Oncology, Boston, USA. 12 NASA, Astronauts, Houston, USA. 13 Weill Cornell Medicine, Radiation Oncology, New York, USA. 14 New York Presbyterian, Radiation Oncology, New York, USA. 15 Assuta Medical Centers, Radiation Oncology, Tel Aviv, Israel. 16 Thomas Jefferson University, Radiation Oncology, Philadelphia, USA. 17 Orlando Health, Radiation Oncology, Orlando, USA

Purpose/Objective:

The phase 2 SMART trial prospectively confirmed that 5-fraction ablative stereotactic magnetic resonance (MR)-guided adaptive radiotherapy (SMART) for borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC) is safe 1 . On-table adaptive plan quality for 5-fraction pancreas SMART has not been well described in the literature. Therefore, our primary objective was to evaluate on-table adaptive plan quality from the phase 2 SMART trial.

Material/Methods: